| Literature DB >> 31632491 |
Jian Tu1, Qiliang Peng2, Yi Shen3, Yin Hong4, Jiahao Zhu5, Zhengyang Feng6, Ping Zhou2, Shaonan Fan2, Yaqun Zhu2, Yongsheng Zhang1.
Abstract
Background: Docetaxel resistance is a cursing problem with adverse effects on the therapeutic efficacy of prostate cancer (PCa), involving interactions among multiple molecular components. Single or limited molecules are not strong enough as prediction biomarkers of drug resistance. Network biomarkers are considered to outperform individual markers in disease characterization.Entities:
Keywords: Bioinformatics analysis; Docetaxel resistance; Network biomarkers; Prostate cancer
Year: 2019 PMID: 31632491 PMCID: PMC6775681 DOI: 10.7150/jca.29032
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Details of candidate miRNA biomarkers
| Reported ID | Official ID | P-value (PCa versus Normal controls) | Number of targets |
|---|---|---|---|
| miR-25 | hsa-miR-25 | 4.46E-11 | 192 |
| miR-17 | hsa-miR-17 | 2.35E-07 | 230 |
| miR-20a | hsa-miR-20a | 6.93E-06 | 210 |
| miR-143 | hsa-miR-143 | 7.57E-06 | 47 |
| miR-31 | hsa-miR-31 | 1.72E-04 | 61 |
| miR-34a | hsa-miR-34a | 2.22E-04 | 110 |
| miR-328 | hsa-miR-328 | 3.17E-04 | 22 |
| miR-181a | hsa-miR-181a | 3.61E-04 | 222 |
| let-7c | hsa-let-7c | 1.06E-03 | 99 |
| miR-200b | hsa-miR-200b | 2.96E-03 | 224 |
| miR-205 | hsa-miR-205 | 6.24E-03 | 79 |
| miR-148a | hsa-miR-148a | 8.77E-03 | 137 |
| miR-21 | hsa-miR-21 | 1.16E-02 | 63 |
Top ten significant GO terms enriched by all the targets of the identified microRNA biomarkers
| Category | GO terms | Number of enriched genes | P-value |
|---|---|---|---|
| Negative regulation of transcription from RNA polymerase II promoter | 99 | 4.44E-11 | |
| Positive regulation of transcription, DNA-templated | 78 | 7.25E-11 | |
| Nervous system development | 44 | 1.13E-06 | |
| Angiogenesis | 35 | 9.96E-06 | |
| Ventricular septum morphogenesis | 11 | 1.37E-05 | |
| Protein transport | 51 | 2.14E-05 | |
| Regulation of actin cytoskeleton organization | 13 | 5.86E-05 | |
| Negative regulation of cell migration | 19 | 7.36E-05 | |
| Negative regulation of stress fiber assembly | 8 | 7.58E-05 | |
| Homophilic cell adhesion via plasma membrane adhesion molecules | 26 | 7.79E-05 | |
| Cytoplasm | 439 | 6.23E-10 | |
| Cytosol | 299 | 1.58E-09 | |
| Nucleoplasm | 250 | 9.07E-08 | |
| Cell-cell adherens junction | 49 | 9.23E-08 | |
| Focal adhesion | 53 | 9.64E-07 | |
| Transcription factor complex | 32 | 3.38E-06 | |
| Golgi apparatus | 92 | 4.72E-06 | |
| Golgi membrane | 68 | 8.79E-06 | |
| Membrane | 194 | 1.20E-05 | |
| Cytoplasmic vesicle membrane | 23 | 2.31E-05 | |
| Protein binding | 736 | 6.79E-19 | |
| Ubiquitin-protein transferase activity | 47 | 2.07E-06 | |
| GTPase activator activity | 40 | 1.24E-05 | |
| Cadherin binding involved in cell-cell adhesion | 41 | 1.31E-05 | |
| Chromatin binding | 50 | 2.09E-05 | |
| Sequence-specific DNA binding | 61 | 2.92E-05 | |
| Ubiquitin protein ligase activity | 29 | 5.93E-05 | |
| mRNA 3'-UTR binding | 13 | 7.63E-05 | |
| Transcription regulatory region DNA binding | 31 | 1.04E-04 | |
| Protein kinase activity | 44 | 1.84E-04 |
The significantly enriched KEGG pathways by all the targets of candidate miRNA biomarkers
| NO. | Pathway term | Number of enriched genes | P-value |
|---|---|---|---|
| 1 | MAPK signaling pathway | 43 | 7.31E-08 |
| 2 | Proteoglycans in cancer | 33 | 5.26E-06 |
| 3 | Pathways in cancer | 51 | 1.29E-05 |
| 4 | PI3K-Akt signaling pathway | 46 | 1.91E-05 |
| 5 | Adherens junction | 16 | 7.52E-05 |
| 6 | Renal cell carcinoma | 15 | 1.04E-04 |
| 7 | TGF-beta signaling pathway | 17 | 1.61E-04 |
| 8 | Dorso-ventral axis formation | 9 | 3.30E-04 |
| 9 | Endocytosis | 32 | 1.56E-03 |
| 10 | Thyroid hormone signaling pathway | 18 | 1.92E-03 |
| 11 | MicroRNAs in cancer | 34 | 2.07E-03 |
| 12 | Ubiquitin mediated proteolysis | 20 | 2.53E-03 |
| 13 | Axon guidance | 19 | 2.56E-03 |
| 14 | Regulation of actin cytoskeleton | 27 | 2.57E-03 |
| 15 | Colorectal cancer | 12 | 3.02E-03 |
| 16 | Ras signaling pathway | 28 | 3.34E-03 |
| 17 | Focal adhesion | 26 | 3.79E-03 |
| 18 | Rap1 signaling pathway | 26 | 4.88E-03 |
| 19 | Wnt signaling pathway | 19 | 6.28E-03 |
| 20 | HIF-1 signaling pathway | 15 | 6.89E-03 |
| 21 | Neurotrophin signaling pathway | 17 | 7.87E-03 |
| 22 | FoxO signaling pathway | 18 | 1.02E-02 |
| 23 | Synaptic vesicle cycle | 11 | 1.03E-02 |
| 24 | Fc gamma R-mediated phagocytosis | 13 | 1.19E-02 |
| 25 | Amoebiasis | 15 | 1.35E-02 |
| 26 | Hippo signaling pathway | 19 | 1.54E-02 |
| 27 | Oocyte meiosis | 15 | 1.70E-02 |
| 28 | Sphingolipid signaling pathway | 16 | 1.73E-02 |
| 29 | GnRH signaling pathway | 13 | 2.15E-02 |
| 30 | TNF signaling pathway | 14 | 2.95E-02 |
| 31 | Central carbon metabolism in cancer | 10 | 3.01E-02 |
| 32 | GABAergic synapse | 12 | 3.07E-02 |
| 33 | ECM-receptor interaction | 12 | 3.56E-02 |
| 34 | Acute myeloid leukemia | 9 | 3.66E-02 |
| 35 | RNA degradation | 11 | 3.75E-02 |
| 36 | p53 signaling pathway | 10 | 3.91E-02 |
| 37 | AMPK signaling pathway | 15 | 4.03E-02 |
| 38 | Melanogenesis | 13 | 4.12E-02 |
| 39 | Retrograde endocannabinoid signaling | 13 | 4.40E-02 |